nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.03.2018 | Epilepsy (CW Bazil, Section Editor)

Treating Immune-Related Epilepsy

verfasst von: Sonal Bhatia, Sarah E. Schmitt

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review explores different treatment modalities for immune-mediated epilepsy, including epilepsy caused by autoantibodies as well as epilepsy in the context of systemic autoimmune disease.

Recent Findings

Autoimmune epilepsy is an increasingly recognized entity. Conventional treatments for epilepsy, such as antiseizure medications and epilepsy surgery, are less successful in treating epilepsy caused by autoimmune disease. Immunomodulatory therapies such as corticosteroids, intravenous immunoglobulin, and plasma exchange are generally more successful in treating immune-mediated epilepsy than conventional epilepsy therapies.

Summary

Autoimmune epilepsy should be considered as a possible etiology for patients with frequent seizures of unknown etiology. The response to immunotherapies is often promising, particularly in patients with antibodies to neuronal cell surface antigens.

Falco-Walter JJ, Scheffer IE, Fisher RS. The new definition and classification of seizures and epilepsy. Epilepsy Res. 2017;139:73–9.CrossRefPubMed

Brenner T, Sills GJ, Hart Y, Howell S, Waters P, Brodie MJ, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia. 2013;54(6):1028–35. https://doi.org/10.1111/epi.12127.CrossRefPubMed

•• Dubey D, Algallaf A, Hayes R, Freeman M, Chen K, Ding K, et al. Neurologic autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol. 2017;74(4):397–402. This study indicates that autoantibodies may be detected in up to 35% of patients with epilepsy of unknown etiology; furthermore, it identifies clinical characteristics that predict the presence of autoantibodies. https://doi.org/10.1001/jamaneurol.2016.5429.CrossRefPubMed

•• Quek AM, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69(5):582–93. This study demonstrated that the majority of patients with known or suspected autoimmune epilepsy will demonstrated a response to immunotherapy within a median time of four months. https://doi.org/10.1001/archneurol.2011.2985.CrossRefPubMedPubMedCentral

Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(3):701–12. https://doi.org/10.1093/brain/awh077.CrossRefPubMed

Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776–85. https://doi.org/10.1016/S1474-4422(10)70137-X.CrossRefPubMedPubMedCentral

Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094–100. https://doi.org/10.1212/WNL.0b013e3182698cd8.CrossRefPubMedPubMedCentral

Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83(6):638–45. https://doi.org/10.1136/jnnp-2011-301237.CrossRefPubMedPubMedCentral

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;4:391–404.CrossRef

10.

Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76(1):82–94. https://doi.org/10.1002/ana.24189.CrossRefPubMed

11.

Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338(1):94–114. https://doi.org/10.1111/nyas.12553.CrossRefPubMed

12.

Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;2:167–77.CrossRef

13.

McCracken L, Zhang J, Greene M, Crivaro A, Gonzalez J, Kamoun M, et al. Improving the antibody-based evaluation of autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e404. https://doi.org/10.1212/NXI.0000000000000404.CrossRefPubMedPubMedCentral

14.

Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(7):1481–94. https://doi.org/10.1093/brain/123.7.1481.CrossRefPubMed

15.

Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900. https://doi.org/10.1002/ana.22307.CrossRefPubMed

16.

Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424–34. https://doi.org/10.1002/ana.21589.CrossRefPubMedPubMedCentral

17.

Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–6. https://doi.org/10.1212/WNL.0b013e3182a9585f.CrossRefPubMedPubMedCentral

18.

Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19–e3. https://doi.org/10.1111/j.1468-1331.2010.03220.x.CrossRefPubMed

19.

Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia. 2013;6:1036–45.CrossRef

20.

•• Feyissa AM, Lόpez Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e353. This study demonstrates the poor response most patients with autoimmune epilepsy have to traditional antiseizure medications, particularly in comparison with immunotherapy. https://doi.org/10.1212/NXI.0000000000000353.CrossRefPubMedPubMedCentral

21.

Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30:57–63. https://doi.org/10.1016/j.seizure.2015.05.017.CrossRefPubMed

22.

Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136(Pt 10):3151–62. https://doi.org/10.1093/brain/awt212.CrossRefPubMed

23.

Beghi E, Shorvon S. Antiepileptic drugs and the immune system. Epilepsia. 2011;52:40–4. https://doi.org/10.1111/j.1528-1167.2011.03035.x.CrossRefPubMed

24.

Bianchi M, Rossoni G, Sacerdote P, Panerai AE, Berti F. Carbamazepine exerts anti-inflammatory effects in the rat. Eur J Pharmacol. 1995;294(1):71–4. https://doi.org/10.1016/0014-2999(95)00516-1.CrossRefPubMed

25.

Himmerich H, Bartsch S, Hamer H, Mergl R, Schönherr J, Petersein C, et al. Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro. Oxidative Med Cell Longev. 2014;2014:8061–2.CrossRef

26.

Almeida V, Pimentel J, Campos A, Bentes C, Maruta C, Morgado C, et al. Surgical control of limbic encephalitis associated with LGI1 antibodies. Epileptic Disord. 2012;14:345–8.PubMed

27.

•• Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129:101–5. This study demonstrates that patients with neuronal antibody have a low likelihood of an Engel class I outcome following epilepsy surgery. https://doi.org/10.1016/j.eplepsyres.2016.12.010.CrossRefPubMed

28.

Muehlebner A, Groeppel G, Pahs G, Hainfellner JA, Prayer D, Czech T, et al. Beneficial effect of epilepsy surgery in a case of childhood non-paraneoplastic limbic encephalitis. Epilepsy Res. 2010;90(3):295–9. https://doi.org/10.1016/j.eplepsyres.2010.05.009.CrossRefPubMed

29.

Mathon B, Bédos Ulvin L, Adam C, Adam C, Baulac M, Dupont S, et al. Surgical treatment for mesial temporal lobe epilepsy associated with hippocampal sclerosis. Rev Neurol (Paris). 2015;171(3):315–25. https://doi.org/10.1016/j.neurol.2015.01.561.CrossRef

30.

Sakuma H, Awaya Y, Shiomi M, Yamanouchi H, Takahashi Y, Saito Y, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand. 2010;121(4):251–6. https://doi.org/10.1111/j.1600-0404.2009.01198.x.CrossRefPubMed

31.

Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–13. https://doi.org/10.1212/WNL.0000000000001940.CrossRefPubMedPubMedCentral

32.

Kramer U, Chi CS, Lin KL, Specchio N, Sahin M, Olson H, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52(11):1956–65. https://doi.org/10.1111/j.1528-1167.2011.03250.x.CrossRefPubMed

33.

Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;8:665–70.CrossRef

34.

Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276–86. https://doi.org/10.1016/S1474-4422(13)70299-0.CrossRefPubMedPubMedCentral

35.

Appavu B, Vanatta L, Condie J, Kerrigan JF, Jarrar R, et al. Ketogenic diet treatment for pediatric super-refractory status epilepticus. Seizure. 2016;41:62–5. https://doi.org/10.1016/j.seizure.2016.07.006.CrossRefPubMed

36.

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. 2011;10:Lancet Neurol, 63–74.

37.

•• Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek AM, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578–86. This study demonstrated that immunotherapy with methylprednisolone or IVIG produces a high rate of seizure reduction/seizure freedom in patients with suspected autoimmunity, even in the absence of an identified autoantibody. https://doi.org/10.1212/WNL.0000000000000383.CrossRefPubMedPubMedCentral

38.

American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Arthritis Rheum. 2001; 44(7):1496–503.

39.

Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis Ann Intern Med. 1991;115(10):787–96. https://doi.org/10.7326/0003-4819-115-10-787.CrossRefPubMed

40.

Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014:(10):CD005590.

41.

Suleiman J, Dale RC. The recognition and treatment of autoimmune epilepsy in children. Dev Med Child Neurol. 2015;57(5):431–40. https://doi.org/10.1111/dmcn.12647.CrossRefPubMed

42.

Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geshwind MD. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol. 2014;71(7):896–900. https://doi.org/10.1001/jamaneurol.2014.463.CrossRefPubMedPubMedCentral

43.

Wong SH, Saunders MD, Larner AJ, Das K, Hart IK. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry. 2010;81(10):1167–9. https://doi.org/10.1136/jnnp.2009.178293.CrossRefPubMed

44.

Toledano M, Pittock SJ. Autoimmune epilepsy. Semin Neurol. 2015;35(03):245–58. https://doi.org/10.1055/s-0035-1552625.CrossRefPubMed

45.

Dogan Onugoren M, Deuretzbacher D, Haensch CA, Hagedorn HJ, Halve S, Isenmann S, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2015;86(9):965–72. https://doi.org/10.1136/jnnp-2014-308814.CrossRefPubMed

46.

Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(Pt 8):2178–92. https://doi.org/10.1093/brain/awu142.CrossRefPubMedPubMedCentral

47.

Guan HZ, Ren HT, Yang XZ, Lu Q, Peng B, Zhu YC, et al. Limbic encephalitis associated with anti-γ-aminobutyric acid B receptor antibodies: a case series from China. Chin Med J. 2015;128(22):3023–8. https://doi.org/10.4103/0366-6999.168989.CrossRefPubMedPubMedCentral

48.

Cui J, Bu H, He J, Zhao Z, Han W, Gao R, et al. The gamma-aminobutyric acid-B receptor (GABAB) encephalitis: clinical manifestations and response to immunotherapy. Int J Neurosci. 2017;6:1–7.CrossRef

49.

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8. https://doi.org/10.1016/S1474-4422(08)70224-2.CrossRefPubMedPubMedCentral

50.

Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71(2):59–72. https://doi.org/10.1097/00005792-199203000-00001.CrossRef

51.

Murinson CC, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008: Dec 9;71(24):1955–8. https://doi.org/10.1212/01.wnl.0000327342.58936.e0.CrossRefPubMedPubMedCentral

52.

Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249(6):745–53. https://doi.org/10.1007/s00415-002-0706-4.CrossRefPubMed

53.

Meinck HM, Faber L, Morgenthaler N, Seissler J, Maile S, Butler M, et al. Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J Neurol Neurosurg Psychiatry. 2001;71(1):100–3. https://doi.org/10.1136/jnnp.71.1.100.CrossRefPubMedPubMedCentral

54.

Gagnon MM, Savard M. Limbic encephalitis associated with GAD65 antibodies: brief review of the relevant literature. Can J Neurol Sci. 2016;43(4):486–93. https://doi.org/10.1017/cjn.2016.13.CrossRefPubMed

55.

Douglas CA, Ellershaw J. Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer. Palliat Med. 2013;17:638–9.CrossRef

56.

Orange D, Frank M, Tian S, Dousmanis A, Marmur R, Buckley N, et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol. 2012;69(9):1132–40. https://doi.org/10.1001/archneurol.2012.595.CrossRefPubMedPubMedCentral

57.

Bertsias GK, Ionnidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–82. https://doi.org/10.1136/ard.2010.130476.CrossRefPubMed

58.

Atwater BD, Ai Z, Wolff MR. Fulminant myopericarditis from phenytoin-induced systemic lupus erythematosus. WMJ. 2008;107(6):298–300.PubMed

59.

Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled trial of IV cyclophosphamide versus IV methylprednidolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620–5. https://doi.org/10.1136/ard.2004.025528.CrossRefPubMedPubMedCentral

60.

Vasconcellos E, Pina-Garza JE, Fakhoury T, Fenichel GM. Pediatric manifestations of Hashimoto’s encephalopathy. Pediatr Neurol. 1999;20(5):394–8. https://doi.org/10.1016/S0887-8994(99)00006-5.CrossRefPubMed

61.

Olmez I, Moses H, Sriram S, Kirshner H, Lagrange AH, Pawate S. Diagnostic and therapeutic aspects of Hashimoto’s encephalopathy. J Neurol Sci. 2013;331(1-2):67–71. https://doi.org/10.1016/j.jns.2013.05.009.CrossRefPubMed

62.

Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60(2):164–71. https://doi.org/10.1001/archneur.60.2.164.CrossRefPubMed

63.

Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17. https://doi.org/10.1001/archneur.1985.04060080095022.CrossRefPubMed

64.

Baumann RJ, Robertson WC Jr. Neurosarcoid presents differently in children than in adults. Pediatrics. 2003;112(6):e480–6. https://doi.org/10.1542/peds.112.6.e480.CrossRefPubMed

65.

Malmgren K, Lycke J, Engman E, Hedström A, Jönsson L, Rydenhag B, et al. Successful epilepsy surgery in a patient with neurosarcoidosis. Epilepsia. 2010;51(6):1101–3. https://doi.org/10.1111/j.1528-1167.2010.02580.x.CrossRefPubMed

66.

Lorentzen AO, Sveberg L, Midtvedt O, Kerty E, Heuser K. Overnight response to infliximab in neurosarcoidosis: a case report and review of infliximab treatment practice. Clin Neuropharmacol. 2014;37(5):142–8. https://doi.org/10.1097/WNF.0000000000000047.CrossRefPubMed

67.

Marnane M, Lynch T, Scott J, Stack J, Kelly PJ. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol. 2009;256(1):139–40.CrossRefPubMed

68.

Alaedini A, Okamoto H, Briani C, Wollenberg K, Shill HA, Bushara KO, et al. Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I. J Immunol. 2007;178(10):6590–5. https://doi.org/10.4049/jimmunol.178.10.6590.CrossRefPubMed

69.

Chapman RW, Laidlow JM, Colin-Jone D, Eade OE, Smith CL. Increased prevalence of epilepsy in celiac disease. BMJ. 1978;22:250–1.CrossRef

70.

Hadijvassiliou M, Grünewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry. 2002;72(5):560–3. https://doi.org/10.1136/jnnp.72.5.560.CrossRef

71.

Ventura A, Bouquet F, Sartorelli C, Barbi E, Torre G, Tommasini G, et al. Coeliac disease, folic acid deficiency and epilepsy with cerebral calcifications. Acta Pediatr Scand. 1991;80(5):559–62. https://doi.org/10.1111/j.1651-2227.1991.tb11906.x.CrossRef

72.

Bye AM, Andermann F, Robitaille Y, Oliver M, Bohane T, Andermann E. Cortical vascular abnormalities in the syndrome of celiac disease, epilepsy, bilateral occipital calcifications and folate deficiency. Ann Neurol. 1993;34(3):399–403. https://doi.org/10.1002/ana.410340316.CrossRefPubMed

73.

Bashiri H, Afshari D, Babaei N, Ghadami MR. Celiac disease and epilepsy: the effect of gluten-free diet on seizure control. Adv Clin Exp Med. 2016;25(4):751–4. https://doi.org/10.17219/acem/43585.CrossRefPubMed

74.

Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol. 1991;48(8):842–4. https://doi.org/10.1001/archneur.1991.00530200084023.CrossRefPubMed

Titel: Treating Immune-Related Epilepsy
verfasst von: Sonal Bhatia
Sarah E. Schmitt
Publikationsdatum: 01.03.2018
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 3/2018
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-018-0821-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Treating Immune-Related Epilepsy

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!

Progressive Supranuclear Palsy: an Update

The Neuropsychological Consequences of Armed Conflicts and Torture

Neurological Complications of Acute and Chronic Otitis Media

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie